GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
  • 1
    In: ACS Chemical Biology, American Chemical Society (ACS), Vol. 17, No. 8 ( 2022-08-19), p. 2377-2378
    Type of Medium: Online Resource
    ISSN: 1554-8929 , 1554-8937
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2022
    detail.hit.zdb_id: 2230027-2
    detail.hit.zdb_id: 2221735-6
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: ACS Chemical Biology, American Chemical Society (ACS), Vol. 14, No. 5 ( 2019-05-17), p. 1020-1029
    Type of Medium: Online Resource
    ISSN: 1554-8929 , 1554-8937
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2019
    detail.hit.zdb_id: 2230027-2
    detail.hit.zdb_id: 2221735-6
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2013
    In:  Neuro-Oncology Vol. 15, No. suppl 3 ( 2013-11-01), p. iii98-iii135
    In: Neuro-Oncology, Oxford University Press (OUP), Vol. 15, No. suppl 3 ( 2013-11-01), p. iii98-iii135
    Type of Medium: Online Resource
    ISSN: 1522-8517 , 1523-5866
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 2028601-6
    detail.hit.zdb_id: 2094060-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Pharmacology Research & Perspectives, Wiley, Vol. 10, No. 4 ( 2022-08)
    Abstract: We recently described the identification of a new class of small‐molecule activators of the mitochondrial protease ClpP. These compounds synthesized by Madera Therapeutics showed increased potency of cancer growth inhibition over the related compound ONC201. In this study, we describe chemical optimization and characterization of the next generation of highly potent and selective small‐molecule ClpP activators (TR compounds) and demonstrate their efficacy against breast cancer models in vitro and in vivo. We selected one compound (TR‐107) with excellent potency, specificity, and drug‐like properties for further evaluation. TR‐107 showed ClpP‐dependent growth inhibition in the low nanomolar range that was equipotent to paclitaxel in triple‐negative breast cancer (TNBC) cell models. TR‐107 also reduced specific mitochondrial proteins, including OXPHOS and TCA cycle components, in a time‐, dose‐, and ClpP‐dependent manner. Seahorse XF analysis and glucose deprivation experiments confirmed the inactivation of OXPHOS and increased dependence on glycolysis following TR‐107 exposure. The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t 1/2 after oral administration. Using human TNBC MDA‐MB‐231 xenografts, the antitumor response to TR‐107 was investigated. Oral administration of TR‐107 resulted in a reduction in tumor volume and extension of survival in the treated compared with vehicle control mice. ClpP activation in vivo was validated by immunoblotting for TFAM and other mitochondrial proteins. In summary, we describe the identification of highly potent new ClpP agonists with improved efficacy against TNBC, through targeted inactivation of OXPHOS and disruption of mitochondrial metabolism.
    Type of Medium: Online Resource
    ISSN: 2052-1707 , 2052-1707
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2740389-0
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Wiley ; 2006
    In:  The FASEB Journal Vol. 20, No. 5 ( 2006-03)
    In: The FASEB Journal, Wiley, Vol. 20, No. 5 ( 2006-03)
    Type of Medium: Online Resource
    ISSN: 0892-6638 , 1530-6860
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2006
    detail.hit.zdb_id: 1468876-1
    detail.hit.zdb_id: 639186-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 5380-5380
    Abstract: Background and goals: ONC201 an experimental anticancer drug, targeting mitochondrial caseinolytic peptidase, ClpP is currently under investigation. Current data on the effect of ONC201 along with observations that ONC201 causes cytotoxic effect, there are data demonstrating that ONC201 is rather cytostatic and does not induce cell death. Recently, we demonstrated ONC201-induced arrest of proliferation and a decrease in the number of mitochondrial nucleoids. Here we extended our study to describe the effect of short-and long-term exposure of BT474 cells to ONC201. Observations: Proliferation and cell cycle arrest. ONC201 in a dose-dependent manner (0-50 µM) inhibited the proliferation of BT474 cells without induction of apoptotic cell death. Cells exposed to 10 µM ONC201 accumulated in G0/G1 phase (49.4 ± 11.5% vs 78.7 ± 5.1%) and declined in the S-phase of the cell cycle (39.2 ± 6.6% vs 9.0 ± 2.1%). In parallel, ONC201 exposure induced a decline in Cyclin E and Cdk2 protein levels. Nucleoids and mtDNA. Exposure of BT474 cells, to 10 µM ONC 201, decreased the number of mitochondrial nucleoids from 249 ± 52 to 155 ± 38 per cell after 24 h. Longer 72 h exposure further reduced the number of nucleoids to 84 ± 36 per cell. ONC201 exposure also induced reduction of mitochondrial size from 2.8 ± 0.5 µm2 to 1.5 ± 0.2 µm2 and depletion of mtDNA. Short-term and long-term consequences of cell exposure to ONC201. Short-term treatment (24 h exposure) demonstrated the reversible effect of ONC201 on the expression of stress proteins (ATF4, CHOP, and GDF-15), cell cycle regulatory proteins (cyclin E, Cdk2), and partial restoration of mitochondrial nucleoids (to 214 ± 46 nucleoids per cell). On the contrary, long-term treatment (72 h) resulted in the irreversible and persistent arrest of proliferation, decline of cell cycle regulatory proteins, and activation of stress proteins. Respiration. ONC201 exposure suppressed State 3, State 4, and uncoupled respiration in digitonin-permeabilized BT474 cells. Complex I activity was decreased from 3.3 ± 0.4 ng-atoms O/min/106 cells to 0.5 ± 0.1 and 0.4 ± 0.3 ng-atoms O/min/106 cells, in cells exposed to ONC201 for 24h and 72h, respectively. Similarly, ONC201 decreased the activity of Complex II from 3.5 ± 0.5 ng-atoms O/min/106 cells to 1.5 ± 0.6 and 0.3 ± 0.1 ng-atoms O/min/106. Conclusions: The consequences of ONC201 treatment were dependent on the duration of exposure to the drug. Short-term (24 h) exposure of BT474 cells resulted in reversible induction of stress proteins (ATF4, CHOP, and GDF-15), which were reversed following 120 h incubation in drug-free media. On the contrary, long-term (72 h) exposure of cells to ONC201 induced irreversible and persistent arrest of proliferation and elevation of expression of stress proteins. Thus, ONC201 can induce prolonged and irreversible elevation of stress proteins and persistent G1/S cell cycle arrest. Citation Format: Artem A. Mishukov, Irina V. Odinokova, Serazhutdin A. Abdullaev, Vitaly K. Zhalimov, Emily M. Fennel, Lucas J. Aponte-Collazo, Paul R. Graves, Lee M. Graves, Ekhson L. Holmuhamedov. Anticancer compound ONC201 induces prolonged stress and arrest of proliferation in BT474 human breast cancer cells without induction of cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5380.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2398-2398
    Abstract: ONC201 is a novel anticancer compound currently in over 20 clinical trials for multiple different cancers, including triple negative breast cancer (TNBC). We recently demonstrated that ONC201 and the more potent TR compounds selectively activate the mitochondrial protease ClpP. While previous studies demonstrated substantial effects on mitochondrial metabolism, the consequences of ClpP activation on cancer cell metabolism are yet to be defined. To investigate this, we performed an unbiased metabolomics and proteomics analysis comparing the effects of ONC201 and TR-57 on the TNBC metabolome and proteome. Consistent with these compounds targeting the mitochondria, our studies identified multiple mitochondrial metabolites and enzymes that were impacted by ClpP activation, such as TCA cycle intermediates and enzymes, heat shock proteins and mitochondrial ribosomal proteins. In addition to previously reported elements of the integrated stress response (ATF4, CHOP), we identified several proteins that were upregulated as part of the mitochondrial-nuclear signaling process. qRT-PCR was used to determine the impact of ONC201 or TR-57 treatment on transcript levels of proteomic hits. Importantly, the effects of ONC201 and the TR compounds on these proteins and cell growth were abolished in ClpP null cells. In summary, our studies further demonstrate that loss of metabolic function in mitochondria contributes to the anticancer activity of these ClpP activator compounds. Citation Format: Emily M. Fennell, Lucas J. Aponte-Collazo, Blake R. Rushing, Yuan-Yuan Li, Wimal Pathmasiri, Joshua D. Wynn, Paul R. Graves, Ekhson L. Holmuhamedov, Laura E. Herring, Edwin J. Iwanowicz, Lee M. Graves. Disruption of mitochondrial metabolism by ClpP activation in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2398.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Elsevier BV ; 2007
    In:  Journal of Biological Chemistry Vol. 282, No. 40 ( 2007-10), p. 29493-29503
    In: Journal of Biological Chemistry, Elsevier BV, Vol. 282, No. 40 ( 2007-10), p. 29493-29503
    Type of Medium: Online Resource
    ISSN: 0021-9258
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2007
    detail.hit.zdb_id: 2997-X
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: The FASEB Journal, Wiley, Vol. 34, No. S1 ( 2020-04), p. 1-1
    Abstract: Approximately 20% of breast cancer cases diagnosed yearly are of the triple‐negative breast cancer (TNBC) type. Current treatments for TNBC patients are limited to surgical intervention and traditional chemotherapies. ONC201 is a recently discovered orally‐active imipridone molecule in phase I/II clinical trials for a large variety of aggressive cancers including glioblastoma, breast, endometrial, and others. We have been studying highly potent analogs of ONC201, known as the TR compounds (TRs), for their efficacy in TNBC. To better understand the mechanism of action, we coupled a TR compound to agarose beads and applied proteomics to identify potential targets. Our studies identified the mitochondrial caseinolytic peptidase (ClpP), as a major ONC201 and TRs binding protein. We further demonstrated that these compounds activated the proteolytic activity of ClpP and that this mitochondrial signal was required for subsequent activation of the integrated stress response as determined by increased CHOP and ATF4 proteins. In addition to activation of the integrated stress response, other recent studies have suggested that the antitumor effects of ONC201 may in part be dependent on increased immune cell recruitment and cancer growth inhibition through this mechanism. Thus, one of our major objectives is to understand how activation of ClpP by ONC201 or TRs impacts cellular signaling events that lead to enhanced immune cell recruitment. We hypothesize that activation of ClpP promotes activation of key immune signaling proteins, like NF‐kB, which subsequently leads to an increase in proteins required for immune cell recruitment. Accordingly, our preliminary data shows activation or up‐regulation of proteins connected to innate immune signaling including MAVS, NF‐kB, and TBK1 in response to ONC201 or TRs treatment. Additionally, our qPCR data shows that treatment of TNBC cells with ONC201 or TRs leads to increased mRNA levels of specific Interleukins (IL‐12, IL‐10). Collectively, these results suggest that activation of ClpP by ONC201 or TRs increases innate immune signaling and expression of cytokines, which are crucial events for successful recruitment of immune cells. Future experiments will evaluate if activation of NF‐κB by ONC201 or TRs treatment is ClpP dependent using a ClpP knockout in TNBC cell lines. Lastly, we will also measure changes in levels of known NF‐κB regulated cytokines (TNFα, IL‐6, IL‐18 and IL‐1β) after treating TNBC cells with ONC201 or TRs using flow cytometry. Overall, this work provides valuable new insight into potential mechanisms by which ClpP activators mediate their anti‐cancer effects through immune signaling and recruitment. Support or Funding Information L.J.A.‐C was supported by the NIH 5 T32 GM007040
    Type of Medium: Online Resource
    ISSN: 0892-6638 , 1530-6860
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1468876-1
    detail.hit.zdb_id: 639186-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: The FASEB Journal, Wiley, Vol. 34, No. S1 ( 2020-04), p. 1-1
    Abstract: ONC201 is an imipridone compound in clinical trials for multiple cancer types, including triple negative breast cancer (TNBC). ONC201 is a promising anticancer therapy whose pharmacological target and function are not clearly defined. We have demonstrated that the target of ONC201 and its potent analogues (TR compounds) is the mitochondrial protease ClpP, consistent with previous reports of ONC201‐induced mitochondrial stress and depolarization in TNBC cells. Study Objective The objective of this study is to determine if ONC201 and TR compound treatment result in a loss of mitochondrial protein through activation of ClpP, leading to metabolic disruption in glutamine utilization and mitochondrial function. Methods To determine if ONC201 and TR compounds disrupt aerobic respiration, galactose was substituted for glucose in cell culture media. We used galactose‐containing cell culture media to shift cells from anaerobic to aerobic respiration, as galactose is utilized through aerobic respiration. The IC 50 of ONC201 and TR compounds was measured with glucose‐ or galactose‐containing media by MTS. MitoPlate assays (Biolog) were performed to identify perturbations in the utilization of 30 different substrates in TNBC cells treated with ONC201 or TR compounds. Proteomic analysis of ONC201 or TR compound‐treated cells was conducted using LC‐MS. Results Proteomic analysis revealed a large decline in mitochondrial peptides following ONC201 or TR compound treatment. We also demonstrated that substitution of glucose with galactose reduced the IC 50 of ONC201 and TR compounds in TNBC cells. In addition, MitoPlate assays suggest a reduced utilization of TCA cycle substrates and L‐glutamine. Conclusions Addition of galactose to cell culture media improved efficacy of ONC201 and TR compounds in TNBC cells. Sensitization and loss of mitochondrial peptides suggest that ONC201 and TR compounds cause loss of mitochondrial protein and reduction metabolic activity. Consistent with sensitization results, MitoPlate data demonstrates a loss of TCA cycle substrate and L‐glutamine utilization following ONC201 or TR compound treatment. Glutamine is known to facilitate both cell proliferation and energy production in cancer cells through protein biosynthesis and the TCA cycle. Proteomic analysis is being used to identify ClpP‐dependent protein loss. Uniformly 13 C‐labeled substrates will be used to identify perturbations in energetic and biosynthetic pathways following ONC201 and TR compound treatment. Loss of mitochondrial metabolic activity and glutamine utilization may play a role in ONC201 and TR compound anticancer activity. Support or Funding Information NIH Pharmacological Sciences T32 (GM007040), University Cancer Research Fund
    Type of Medium: Online Resource
    ISSN: 0892-6638 , 1530-6860
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1468876-1
    detail.hit.zdb_id: 639186-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...